BerGenBio Overview

  • Founded
  • 2007
  • Status
  • Public
  • Employees
  • 46
  • Stock Symbol
Stock Symbol
  • Share Price
  • $2.54
  • (As of Friday Closing)

BerGenBio General Information


BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Primary Office
  • Jonas Lies vei 91
  • 5009 Bergen
  • Norway
+47 55 00 00 00

BerGenBio Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BerGenBio Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.54 $2.49 $2.35 - $4.73 $224M 88.2M 186K -$0.41

BerGenBio Financials Summary

In Thousands,
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 170,242 246,495 136,729 118,814
Revenue 68 64 1,011 287
EBITDA (35,864) (27,550) (22,792) (23,947)
Net Income (35,421) (27,163) (22,637) (23,546)
Total Assets 68,300 86,473 30,657 43,481
Total Debt 145 236 66 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BerGenBio Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BerGenBio‘s full profile, request access.

Request a free trial

BerGenBio Executive Team (12)

Name Title Board Seat Contact Info
Richard Godfrey Chief Executive Officer
Rune Skeie Chief Financial Officer
David Micklem Ph.D Co-Founder & Chief Technology Officer
James Lorens Co-Founder & Chief Scientific Officer
Hani Gabra Chief Medical Officer
You’re viewing 5 of 12 executive team members. Get the full list »

BerGenBio Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial